Enhance.MD vs Oak Longevity: Which Is Cheaper?
Released · Last reviewed
Both programmes priced at a standard therapeutic dose, with the subtraction shown for each molecule separately.
Which is cheaper: the arithmetic
Standard therapeutic dosing only. Each price was read on the program's own page on October 15, 2026; "all-in" adds any required membership. Each molecule is answered separately, because the two are priced differently at the same provider.
Tirzepatide: no subtraction is possible on October 15, 2026: Oak Longevity has no comparable price because its own pages print no product price for it. Enhance.MD's lowest all-in price is $280 per 4-week cycle.
Semaglutide: no subtraction is possible on October 15, 2026: Oak Longevity has no comparable price because its own pages print no product price for it. Enhance.MD's lowest all-in price is $212 per 4-week cycle.
Figures come from our published dataset (read 2026-10-15). Microdose tiers are excluded: they sit below every dose the pivotal trials studied. A lower price on a 3-, 6- or 12-month plan usually means paying for that term, and compounded medication is generally not refundable once shipped.
What the price does not tell you
Whether the dispensing pharmacy is named before purchase, which is the only verification available to you before money changes hands. What the cancellation terms are, and what is refundable once medication has shipped. Whether laboratory work is required and billed separately. And whether a clinician licensed in your state is available, which decides whether the programme can serve you at all.
Full profiles: Enhance.MD and Oak Longevity. Complete rankings at the semaglutide and tirzepatide comparison tables.
Compounded GLP-1 medicines are not FDA-approved and are not therapeutically equivalent to any brand-name product. This is consumer price research, not medical advice.
The numbers behind this page
What we do not claim in this comparison
Every price quoted in this comparison comes from the programme's own pricing page and carries the date it was captured.
We do not claim these prices will hold. Compounded pricing moves within weeks, and a figure without a capture date is not a fact. We do not claim a compounded preparation is equivalent to an approved product: it is not FDA-approved, is not therapeutically equivalent to any brand-name product, and FDA does not review it for safety, effectiveness or manufacturing quality before marketing.
And we do not claim to be a clinical resource. Which molecule suits you, at what dose, and whether treatment is appropriate at all are questions for a prescribing clinician who has your history. This is price research, and it is only useful once those questions are settled.
Reading the price against the market
What the plan term is worth
The figures in this comparison sit inside a market with a measurable shape, and that shape is what makes any single price readable.
Several programmes publish two prices: the advertised rate, which requires a commitment, and the month-to-month rate, which does not. The gap between them is the price of flexibility, and it is rarely presented that way.
Compounded medication is generally not refundable once shipped, and most discontinuation happens in the first three months — precisely the window a twelve-month prepayment covers. Committing at signup and committing after reaching a dose you tolerate are materially different decisions, even though the advertised rate is identical.
We show month-to-month and prepaid figures side by side for that reason. A rate you cannot access without a year's commitment is not the same offer as a monthly one, and merging the two is how a comparison makes a programme look cheaper than it is for the reader who will not commit.
Questions this page answers
Are compounded GLP-1 medicines FDA-approved?
No. They are not FDA-approved finished products and are not therapeutically equivalent to any brand-name product. FDA does not review them for safety, effectiveness or manufacturing quality before marketing.
Why do the same programmes quote two different prices?
Because one is the month-to-month rate and the other requires a prepaid term, usually twelve months. We compare programs on their lowest all-in monthly price and print the plan term beside every figure, so a rate that needs a commitment is labelled as one.
Where do these prices come from?
Each is read from the program's own pricing page and carries its read date. The October 15, 2026 file at /api/prices.json holds 106 records, 49 of them verified standard-dose prices, with molecule, dose class and evidence status on every record.
Which tracked programs charge less than NexLife?
Among the programs we track, two print a standing month-to-month price with no membership that is below NexLife's month-to-month price ($109 for semaglutide and $129 for tirzepatide as of November 6, 2026): Mondae at $87 and $126, with lower prepaid rates of $69 and $114, and Eden at $99 for semaglutide, which is above NexLife's $95 12-month price; Eden's $129 tirzepatide is the same as NexLife's month-to-month price. Competitor prices were read on October 15, 2026. Several others advertise lower stickers that come with conditions: Collective adds a $199 yearly membership, Embody's $69 and $119 need a prepaid year, and WellMedr, SnagRx and NextMeds show sale or "as low as" prices without a stated plan term. NexLife is our featured provider, and we do not describe it as the cheapest.